Physician profile
Patrick Farley
NPI 1922051549
$6,421.25
in general payments reported to CMS, 2019-2025
28 companies · $4,165 in 2025
The $4,165 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $932 · 2023: $131 · 2024: $1,194 · 2025: $4,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,129 · Education: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,129.03 |
| Education | $360.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $1,009.38 | 2022-2024 | Iovera, Zilretta |
| Abbvie INC. | $793.12 | 2024-2025 | |
| Janssen Biotech, INC. | $710.48 | 2024-2025 | Tremfya |
| Ani Pharmaceuticals, INC. | $616.56 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Ucb, INC. | $614.93 | 2024-2025 | Bimzelx, Cimzia |
| Amgen INC. | $507.74 | 2024-2025 | Tavneos, Evenity, Krystexxa |
| Novartis Pharmaceuticals Corporation | $454.02 | 2024-2025 | |
| Lilly USA, LLC | $243.89 | 2024-2025 | Taltz |
| Aurinia Pharma U.S., INC. | $157.89 | 2023-2025 | Lupkynis |
| Pfizer INC. | $140.23 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $138.15 | 2025 | Tremfya |
| Alexion Pharmaceuticals, INC. | $128.11 | 2024-2025 | Strensiq |
| Sobi, INC | $119.89 | 2024-2025 | |
| Radius Health, INC. | $117.32 | 2025 | Tymlos |
| Mallinckrodt Hospital Products INC. | $100.41 | 2024-2025 | Acthar |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $87.73 | 2025 | Benlysta |
| Fresenius Kabi USA, LLC | $85.95 | 2024-2025 | Idacio |
| Organon LLC | $71.36 | 2025 | Hadlima, Renflexis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.90 | 2024 | Spevigo |
| Kyowa Kirin, INC. | $41.67 | 2025 | |
| Bioventus LLC | $35.10 | 2025 | Durolane |
| Astrazeneca Pharmaceuticals LP | $33.75 | 2024 | Saphnelo |
| Genentech USA, INC. | $30.28 | 2025 | Actemra |
| Kiniksa Pharmaceuticals International, Plc | $28.35 | 2024 | Arcalyst |
| Invivyd INC | $28.06 | 2025 | Pemgarda |
| Fidia Pharma USA INC. | $23.40 | 2025 | Hymovis |
| E.R. Squibb & Sons, L.L.C. | $20.24 | 2025 | Orencia |
| Regeneron Healthcare Solutions, INC. | $18.34 | 2025 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Farley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.